BerandaN1BI34 • BVMF
add
Neurocrine Biosciences Bdr
Tutup sebelumnya
R$41,92
Rentang tahun
R$30,55 - R$43,88
Kapitalisasi pasar
14,43Â M USD
Volume Rata-Rata
578,00
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 622,10Â jt | 24,72% |
Biaya operasional | 234,30Â jt | 14,74% |
Laba bersih | 129,80Â jt | 56,20% |
Margin laba bersih | 20,86 | 25,21% |
Penghasilan per saham | 1,81 | 17,53% |
EBITDA | 191,30Â jt | 30,40% |
Tarif pajak efektif | 31,79% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 1,23Â M | 12,14% |
Total aset | 3,54Â M | 24,11% |
Total liabilitas | 816,10Â jt | -3,55% |
Total ekuitas | 2,72 M | — |
Saham yang beredar | 101,25 jt | — |
Harga terhadap nilai buku | 1,56 | — |
Tingkat pengembalian aset | 13,51% | — |
Tingkat pengembalian modal | 15,91% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 129,80Â jt | 56,20% |
Kas dari operasi | 158,00Â jt | -25,47% |
Kas dari investasi | 24,70Â jt | 125,39% |
Kas dari pembiayaan | 26,40Â jt | 40,43% |
Perubahan kas bersih | 209,40Â jt | 56,85% |
Arus kas bebas | -10,40Â jt | -106,50% |
Tentang
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Didirikan
1992
Kantor pusat
Situs
Karyawan
1.700
